Global Analgesics Market to Reach $59.2 Billion by 2026

ReportLinker

Abstract: What`s New for 2022? -Global competitiveness and key competitor percentage market shares. -Market presence across multiple geographies - Strong/Active/Niche/Trivial.

New York, June 17, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Analgesics Industry" - https://www.reportlinker.com/p05817895/?utm_source=GNW
-Online interactive peer-to-peer collaborative bespoke updates
-Access to our digital archives and MarketGlass Research Platform
-Complimentary updates for one year

Global Analgesics Market to Reach $59.2 Billion by 2026

Pain management continues to be one of the most sought-after treatment options for patients within the healthcare arena that underscores the critical significance of analgesics. Analgesics are drugs meant for pain control primarily. The drugs work on the CNS and peripheral nervous system for reducing or blocking pain sensitivity. There are also analgesics which work by preventing creation of pain mediating chemicals in the body. Widely used for treatment of mild to acute pain attributed to several medical conditions, injuries, surgeries and terminal disorders, analgesics have ruled the pain management domain for the past several decades. These medications have provided medical practitioners with an effective option to alleviate pain and help improve quality of life for patients. Amid the COVID-19 crisis, the global market for Analgesics estimated at US$45.1 Billion in the year 2020, is projected to reach a revised size of US$59.2 Billion by 2026, growing at a CAGR of 4.7% over the analysis period. Prescription, one of the segments analyzed in the report, is projected to grow at a 4.4% CAGR to reach US$37.7 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the OTC segment is readjusted to a revised 5.1% CAGR for the next 7-year period. This segment currently accounts for a 38.2% share of the global Analgesics market.

The U.S. Market is Estimated at $15.2 Billion in 2021, While China is Forecast to Reach $8.2 Billion by 2026

The Analgesics market in the U.S. is estimated at US$15.2 Billion in the year 2021. The country currently accounts for a 32.76% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$8.2 Billion in the year 2026 trailing a CAGR of 6.5% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.3% and 3.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR while Rest of European market (as defined in the study) will reach US$8.8 Billion by the close of the analysis period.

Growth in these markets are benefiting from increasing incidence of diseases like cancer, arthritis, CVD, and also other acute and chronic diseases which causes severe pain. Cancer pain, neuropathic pain, post-operative pain, and lower back pain represent the important market segments. Increasing incidence of cancer globally is poised to be a key driving force for market growth. Further, increasing prevalence of chronic diseases has also fostered the use of pain management therapeutics. Increasing innovation in the area, owing to increased research investment by drug development companies, for advancing combination of compounds for developing new and more effective analgesics with enhanced efficacy as well as fewer side effects, is another prominent factor contributing towards market growth.

Opioids Segment to Reach $18.4 Billion by 2026

Opioid analgesic drugs represent the gold standard in pain relieving treatment of critically ill patients across disease segments, including COVID-19. Fentanyl, morphine, and hydromorphone are among the most commonly used IV opioid analgesic drugs in the ICU settings for COVID as well as non-COVID patients. Global Opioids segment is estimated at US$14.9 Billion in 2020, and is projected to reach US$18.4 Billion by 2026 reflecting a compounded annual growth rate of 3.7% over the analysis period. United States constitutes the largest regional market for Opioids segment, accounting for 29.9% of the global sales in 2020. China is poised to register the fastest compounded annual growth rate of 5.2% over the analysis period, to reach US$2.6 Billion by 2026.
Select Competitors (Total 146 Featured) -

• Amneal Pharmaceuticals Inc

• Apotex Inc

• AstraZeneca Plc

• Aurobindo Pharma Limited

• Bausch Health Companies Inc.

• Bayer AG

• Cipla Limited

• Eli Lilly and Company

• Endo International plc

• F. Hoffmann-La Roche AG

• Fresenius Kabi AG

• GlaxoSmithKline PLC

• Hikma Pharmaceuticals PLC

• Iroko Pharmaceuticals, LLC

• Johnson & Johnson

• Lupin Limited

• Novartis AG

• Reckitt Benckiser Group plc

• Sanofi S.A.

• Sun Pharmaceutical Industries Ltd

• Teva Pharmaceutical Industries Ltd

Read the full report: https://www.reportlinker.com/p05817895/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Analgesics - Global Key Competitors Percentage Market Share in
2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession
A Prelude to Analgesics
Analgesics: Perfect Therapeutic Options to Solve Mild to
Crippling Pain
Key Segments
Opioid Analgesics
Non-Opioid Analgesics
NSAIDs
Topical NSAIDs
Others
Acetaminophen
Adjuvant Analgesics
Impact of COVID-19 on Analgesics
NSAIDs
NSAIDs Tend to Decrease Effectiveness of COVID-19 Vaccines,
States a Yale University Study
Opioid
Acetaminophen
Global Analgesics Market to Witness Rapid Growth
Drugs Indicated for Pain Management
The US and Europe Represent the Largest Regions, Asia-Pacific
to Witness fastest Growth
Non-Opioids: Fastest Growing Category
Competition
Recent Market Activity

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS
Growing Aging Population & Increasing Burden of Chronic
Diseases Spurs
Global Population Statistics for the 65+ Age Group in Million
by Geographic Region for the Years 2019, 2025, 2035 and 2050
Fatalities by Heart Conditions: Estimated Percentage Breakdown
for Cardiovascular Disease, Ischemic Heart Disease, Stroke,
and Others
Rising Diabetes Prevalence Presents Opportunity for Cell
Surface Markers: Number of Adults (20-79) with Diabetes
(in Millions) by Region for 2017 and 2045
Growing Incidence of Cancer and the Associated Pain to Drive
the Analgesics Market
Global Cancer Incidence: Number of New Cancer Cases in Million
for the Years 2018, 2020, 2025, 2030, 2035 and 2040
Global Number of New Cancer Cases and Cancer-related Deaths by
Cancer Site for 2018
Number of New Cancer Cases and Deaths (in Million) by Region
for 2018
Advancements in Design and Delivery of Analgesic Drugs
Development of Safer Opioids with More Safer Profiles
Drug Pipeline with Efficacious Drugs
OTC Analgesics Market to Witness Fastest Growth
Topical Analgesics Market Holds Significant Share
Combination Therapies Gain Prominence
A Few Novel Analgesic Products under Development
E-commerce Platforms Strengthen Pharmaceutical Distribution in
Crisis Period
Neuropathic Pain Management: Market with High Potential
Migraine Market: A Core Vertical in CNS Pain Management
Migraine Care: Select Patent Expiries (2013-2015)
Reyvow, Eli Lilly?s Novel Migraine Drug with the Potential to
Lead the Global Migraine Medications Market
Three New Migraine Drugs Obtain FDA Approval
Eli Lilly?s Emgality Receives FDA Approval
Increasing Cases of Peripheral Nerve Injuries Drive the
Analgesics Market

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Prescription by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Prescription by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 3: World 15-Year Perspective for Prescription by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 4: World Recent Past, Current & Future Analysis for OTC
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 5: World Historic Review for OTC by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for OTC by Geographic Region -
Percentage Breakdown of Value Sales for USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa for Years 2012, 2021 & 2027

Table 7: World Recent Past, Current & Future Analysis for
Opioids by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Opioids by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 9: World 15-Year Perspective for Opioids by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 10: World Recent Past, Current & Future Analysis for
NSAIDs by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for NSAIDs by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 12: World 15-Year Perspective for NSAIDs by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 13: World Recent Past, Current & Future Analysis for
Other Drug Classes by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 14: World Historic Review for Other Drug Classes by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Other Drug Classes by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 16: World Recent Past, Current & Future Analysis for Oral
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 17: World Historic Review for Oral by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Oral by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 19: World Recent Past, Current & Future Analysis for
Parenteral by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Parenteral by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 21: World 15-Year Perspective for Parenteral by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 22: World Recent Past, Current & Future Analysis for
Topical by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 23: World Historic Review for Topical by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 24: World 15-Year Perspective for Topical by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 25: World Recent Past, Current & Future Analysis for
Transdermal by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 26: World Historic Review for Transdermal by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 27: World 15-Year Perspective for Transdermal by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 28: World Recent Past, Current & Future Analysis for
Rectal by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 29: World Historic Review for Rectal by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 30: World 15-Year Perspective for Rectal by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 31: World Recent Past, Current & Future Analysis for
Analgesics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 32: World Historic Review for Analgesics by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 33: World 15-Year Perspective for Analgesics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2012, 2021 & 2027

III. MARKET ANALYSIS

UNITED STATES
Analgesics Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in the United States for 2022 (E)
Table 34: USA Recent Past, Current & Future Analysis for
Analgesics by Drug Type - Prescription and OTC - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 35: USA Historic Review for Analgesics by Drug Type -
Prescription and OTC Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 36: USA 15-Year Perspective for Analgesics by Drug Type -
Percentage Breakdown of Value Sales for Prescription and OTC
for the Years 2012, 2021 & 2027

Table 37: USA Recent Past, Current & Future Analysis for
Analgesics by Drug Class - Opioids, NSAIDs and Other Drug
Classes - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 38: USA Historic Review for Analgesics by Drug Class -
Opioids, NSAIDs and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 39: USA 15-Year Perspective for Analgesics by Drug Class -
Percentage Breakdown of Value Sales for Opioids, NSAIDs and
Other Drug Classes for the Years 2012, 2021 & 2027

Table 40: USA Recent Past, Current & Future Analysis for
Analgesics by Route Of Administration - Oral, Parenteral,
Topical, Transdermal and Rectal - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 41: USA Historic Review for Analgesics by Route Of
Administration - Oral, Parenteral, Topical, Transdermal and
Rectal Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 42: USA 15-Year Perspective for Analgesics by Route Of
Administration - Percentage Breakdown of Value Sales for Oral,
Parenteral, Topical, Transdermal and Rectal for the Years 2012,
2021 & 2027

CANADA
Table 43: Canada Recent Past, Current & Future Analysis for
Analgesics by Drug Type - Prescription and OTC - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 44: Canada Historic Review for Analgesics by Drug Type -
Prescription and OTC Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 45: Canada 15-Year Perspective for Analgesics by Drug
Type - Percentage Breakdown of Value Sales for Prescription and
OTC for the Years 2012, 2021 & 2027

Table 46: Canada Recent Past, Current & Future Analysis for
Analgesics by Drug Class - Opioids, NSAIDs and Other Drug
Classes - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 47: Canada Historic Review for Analgesics by Drug Class -
Opioids, NSAIDs and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 48: Canada 15-Year Perspective for Analgesics by Drug
Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs
and Other Drug Classes for the Years 2012, 2021 & 2027

Table 49: Canada Recent Past, Current & Future Analysis for
Analgesics by Route Of Administration - Oral, Parenteral,
Topical, Transdermal and Rectal - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 50: Canada Historic Review for Analgesics by Route Of
Administration - Oral, Parenteral, Topical, Transdermal and
Rectal Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 51: Canada 15-Year Perspective for Analgesics by Route Of
Administration - Percentage Breakdown of Value Sales for Oral,
Parenteral, Topical, Transdermal and Rectal for the Years 2012,
2021 & 2027

JAPAN
Analgesics Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in Japan for 2022 (E)
Table 52: Japan Recent Past, Current & Future Analysis for
Analgesics by Drug Type - Prescription and OTC - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 53: Japan Historic Review for Analgesics by Drug Type -
Prescription and OTC Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 54: Japan 15-Year Perspective for Analgesics by Drug Type -
Percentage Breakdown of Value Sales for Prescription and OTC
for the Years 2012, 2021 & 2027

Table 55: Japan Recent Past, Current & Future Analysis for
Analgesics by Drug Class - Opioids, NSAIDs and Other Drug
Classes - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 56: Japan Historic Review for Analgesics by Drug Class -
Opioids, NSAIDs and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 57: Japan 15-Year Perspective for Analgesics by Drug
Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs
and Other Drug Classes for the Years 2012, 2021 & 2027

Table 58: Japan Recent Past, Current & Future Analysis for
Analgesics by Route Of Administration - Oral, Parenteral,
Topical, Transdermal and Rectal - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 59: Japan Historic Review for Analgesics by Route Of
Administration - Oral, Parenteral, Topical, Transdermal and
Rectal Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 60: Japan 15-Year Perspective for Analgesics by Route Of
Administration - Percentage Breakdown of Value Sales for Oral,
Parenteral, Topical, Transdermal and Rectal for the Years 2012,
2021 & 2027

CHINA
Analgesics Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in China for 2022 (E)
Table 61: China Recent Past, Current & Future Analysis for
Analgesics by Drug Type - Prescription and OTC - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 62: China Historic Review for Analgesics by Drug Type -
Prescription and OTC Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 63: China 15-Year Perspective for Analgesics by Drug Type -
Percentage Breakdown of Value Sales for Prescription and OTC
for the Years 2012, 2021 & 2027

Table 64: China Recent Past, Current & Future Analysis for
Analgesics by Drug Class - Opioids, NSAIDs and Other Drug
Classes - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 65: China Historic Review for Analgesics by Drug Class -
Opioids, NSAIDs and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 66: China 15-Year Perspective for Analgesics by Drug
Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs
and Other Drug Classes for the Years 2012, 2021 & 2027

Table 67: China Recent Past, Current & Future Analysis for
Analgesics by Route Of Administration - Oral, Parenteral,
Topical, Transdermal and Rectal - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 68: China Historic Review for Analgesics by Route Of
Administration - Oral, Parenteral, Topical, Transdermal and
Rectal Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 69: China 15-Year Perspective for Analgesics by Route Of
Administration - Percentage Breakdown of Value Sales for Oral,
Parenteral, Topical, Transdermal and Rectal for the Years 2012,
2021 & 2027

EUROPE
Analgesics Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in Europe for 2022 (E)
Table 70: Europe Recent Past, Current & Future Analysis for
Analgesics by Drug Type - Prescription and OTC - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 71: Europe Historic Review for Analgesics by Drug Type -
Prescription and OTC Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 72: Europe 15-Year Perspective for Analgesics by Drug
Type - Percentage Breakdown of Value Sales for Prescription and
OTC for the Years 2012, 2021 & 2027

Table 73: Europe Recent Past, Current & Future Analysis for
Analgesics by Drug Class - Opioids, NSAIDs and Other Drug
Classes - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 74: Europe Historic Review for Analgesics by Drug Class -
Opioids, NSAIDs and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 75: Europe 15-Year Perspective for Analgesics by Drug
Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs
and Other Drug Classes for the Years 2012, 2021 & 2027

Table 76: Europe Recent Past, Current & Future Analysis for
Analgesics by Route Of Administration - Oral, Parenteral,
Topical, Transdermal and Rectal - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 77: Europe Historic Review for Analgesics by Route Of
Administration - Oral, Parenteral, Topical, Transdermal and
Rectal Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 78: Europe 15-Year Perspective for Analgesics by Route Of
Administration - Percentage Breakdown of Value Sales for Oral,
Parenteral, Topical, Transdermal and Rectal for the Years 2012,
2021 & 2027

Table 79: Europe Recent Past, Current & Future Analysis for
Analgesics by Geographic Region - France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 80: Europe Historic Review for Analgesics by Geographic
Region - France, Germany, Italy, UK, Spain, Russia and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 81: Europe 15-Year Perspective for Analgesics by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2012, 2021 & 2027

FRANCE
Analgesics Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in France for 2022 (E)
Table 82: France Recent Past, Current & Future Analysis for
Analgesics by Drug Type - Prescription and OTC - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 83: France Historic Review for Analgesics by Drug Type -
Prescription and OTC Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 84: France 15-Year Perspective for Analgesics by Drug
Type - Percentage Breakdown of Value Sales for Prescription and
OTC for the Years 2012, 2021 & 2027

Table 85: France Recent Past, Current & Future Analysis for
Analgesics by Drug Class - Opioids, NSAIDs and Other Drug
Classes - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 86: France Historic Review for Analgesics by Drug Class -
Opioids, NSAIDs and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 87: France 15-Year Perspective for Analgesics by Drug
Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs
and Other Drug Classes for the Years 2012, 2021 & 2027

Table 88: France Recent Past, Current & Future Analysis for
Analgesics by Route Of Administration - Oral, Parenteral,
Topical, Transdermal and Rectal - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 89: France Historic Review for Analgesics by Route Of
Administration - Oral, Parenteral, Topical, Transdermal and
Rectal Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 90: France 15-Year Perspective for Analgesics by Route Of
Administration - Percentage Breakdown of Value Sales for Oral,
Parenteral, Topical, Transdermal and Rectal for the Years 2012,
2021 & 2027

GERMANY
Analgesics Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in Germany for 2022 (E)
Table 91: Germany Recent Past, Current & Future Analysis for
Analgesics by Drug Type - Prescription and OTC - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 92: Germany Historic Review for Analgesics by Drug Type -
Prescription and OTC Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 93: Germany 15-Year Perspective for Analgesics by Drug
Type - Percentage Breakdown of Value Sales for Prescription and
OTC for the Years 2012, 2021 & 2027

Table 94: Germany Recent Past, Current & Future Analysis for
Analgesics by Drug Class - Opioids, NSAIDs and Other Drug
Classes - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 95: Germany Historic Review for Analgesics by Drug Class -
Opioids, NSAIDs and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 96: Germany 15-Year Perspective for Analgesics by Drug
Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs
and Other Drug Classes for the Years 2012, 2021 & 2027

Table 97: Germany Recent Past, Current & Future Analysis for
Analgesics by Route Of Administration - Oral, Parenteral,
Topical, Transdermal and Rectal - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 98: Germany Historic Review for Analgesics by Route Of
Administration - Oral, Parenteral, Topical, Transdermal and
Rectal Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 99: Germany 15-Year Perspective for Analgesics by Route
Of Administration - Percentage Breakdown of Value Sales for
Oral, Parenteral, Topical, Transdermal and Rectal for the Years
2012, 2021 & 2027

ITALY
Table 100: Italy Recent Past, Current & Future Analysis for
Analgesics by Drug Type - Prescription and OTC - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 101: Italy Historic Review for Analgesics by Drug Type -
Prescription and OTC Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 102: Italy 15-Year Perspective for Analgesics by Drug
Type - Percentage Breakdown of Value Sales for Prescription and
OTC for the Years 2012, 2021 & 2027

Table 103: Italy Recent Past, Current & Future Analysis for
Analgesics by Drug Class - Opioids, NSAIDs and Other Drug
Classes - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 104: Italy Historic Review for Analgesics by Drug Class -
Opioids, NSAIDs and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 105: Italy 15-Year Perspective for Analgesics by Drug
Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs
and Other Drug Classes for the Years 2012, 2021 & 2027

Table 106: Italy Recent Past, Current & Future Analysis for
Analgesics by Route Of Administration - Oral, Parenteral,
Topical, Transdermal and Rectal - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 107: Italy Historic Review for Analgesics by Route Of
Administration - Oral, Parenteral, Topical, Transdermal and
Rectal Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 108: Italy 15-Year Perspective for Analgesics by Route Of
Administration - Percentage Breakdown of Value Sales for Oral,
Parenteral, Topical, Transdermal and Rectal for the Years 2012,
2021 & 2027

UNITED KINGDOM
Analgesics Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in the United Kingdom for 2022 (E)
Table 109: UK Recent Past, Current & Future Analysis for
Analgesics by Drug Type - Prescription and OTC - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 110: UK Historic Review for Analgesics by Drug Type -
Prescription and OTC Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 111: UK 15-Year Perspective for Analgesics by Drug Type -
Percentage Breakdown of Value Sales for Prescription and OTC
for the Years 2012, 2021 & 2027

Table 112: UK Recent Past, Current & Future Analysis for
Analgesics by Drug Class - Opioids, NSAIDs and Other Drug
Classes - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 113: UK Historic Review for Analgesics by Drug Class -
Opioids, NSAIDs and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 114: UK 15-Year Perspective for Analgesics by Drug Class -
Percentage Breakdown of Value Sales for Opioids, NSAIDs and
Other Drug Classes for the Years 2012, 2021 & 2027

Table 115: UK Recent Past, Current & Future Analysis for
Analgesics by Route Of Administration - Oral, Parenteral,
Topical, Transdermal and Rectal - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 116: UK Historic Review for Analgesics by Route Of
Administration - Oral, Parenteral, Topical, Transdermal and
Rectal Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 117: UK 15-Year Perspective for Analgesics by Route Of
Administration - Percentage Breakdown of Value Sales for Oral,
Parenteral, Topical, Transdermal and Rectal for the Years 2012,
2021 & 2027

SPAIN
Table 118: Spain Recent Past, Current & Future Analysis for
Analgesics by Drug Type - Prescription and OTC - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 119: Spain Historic Review for Analgesics by Drug Type -
Prescription and OTC Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 120: Spain 15-Year Perspective for Analgesics by Drug
Type - Percentage Breakdown of Value Sales for Prescription and
OTC for the Years 2012, 2021 & 2027

Table 121: Spain Recent Past, Current & Future Analysis for
Analgesics by Drug Class - Opioids, NSAIDs and Other Drug
Classes - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 122: Spain Historic Review for Analgesics by Drug Class -
Opioids, NSAIDs and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 123: Spain 15-Year Perspective for Analgesics by Drug
Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs
and Other Drug Classes for the Years 2012, 2021 & 2027

Table 124: Spain Recent Past, Current & Future Analysis for
Analgesics by Route Of Administration - Oral, Parenteral,
Topical, Transdermal and Rectal - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 125: Spain Historic Review for Analgesics by Route Of
Administration - Oral, Parenteral, Topical, Transdermal and
Rectal Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 126: Spain 15-Year Perspective for Analgesics by Route Of
Administration - Percentage Breakdown of Value Sales for Oral,
Parenteral, Topical, Transdermal and Rectal for the Years 2012,
2021 & 2027

RUSSIA
Table 127: Russia Recent Past, Current & Future Analysis for
Analgesics by Drug Type - Prescription and OTC - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 128: Russia Historic Review for Analgesics by Drug Type -
Prescription and OTC Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 129: Russia 15-Year Perspective for Analgesics by Drug
Type - Percentage Breakdown of Value Sales for Prescription and
OTC for the Years 2012, 2021 & 2027

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p05817895/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001